Histiocytic sarcoma progressing from follicular lymphoma and mimicking acquired hemophagocytic lymphohistiocytosis

Dear Editor, Histiocytic sarcoma (HS) is a rare and aggressive nonLangerhans cell histiocytosis with a poor prognosis [1]. In a subset of cases, HS is clonally related to concurrent hematological malignancies, especially lymphomas [2]. Acquired hemophagocytic lymphohistiocytosis (HLH) is a systemic reactive process that includes macrophage activation with hemophagocytosis in the bone marrow [3]. A 57-year-old woman presented with a progressive hypopharyngeal tumor. B symptoms were absent, and laboratory results were unremarkable. Histologic examination showed a blastic infiltration with monocytoid/histiocytic morphology with CD68, CD163, CD14, and lysozyme expression (CD1a, CD3, CD20, CD34, CD56, CD117, MPO and S100 negative, immunohistochemistry (IHC)) (Fig. 1a). Staging revealed mediastinal, mesenterial, and retroperitoneal lymphadenopathy as well as an incidental follicular lymphoma (FL) grade 1 in the bone marrow with otherwise unaffected hematopoiesis. Histiocyte infiltration of the bone marrow was excluded. Fluorescence in situ hybridization (FISH) revealed the presence of translocation t(14;18) within the cervical HS as wel l a s the FL of the bone mar row (F ig . 1b ) . Immunoglobulin heavy chain (IgH) rearrangement was present in the FL but absent in the cervical HS (PCR amplification).We diagnosed HS probably arising from follicular lymphoma. We initiated a therapy with R-CHOEP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone with etoposide) and documented a stable disease after two cycles of therapy. Subsequently, therapy continuation was delayed due to persisting fever. Extensive diagnostics and empiric antimicrobial therapies failed. The patient’s general condition markedly worsened with onset of a sepsis-like syndrome with a high fever, tachycardia, and hypotension as well as an unexplained progressive pancytopenia. Another bone marrow aspirate showed slightly increased cellularity, normal hematopoiesis, and extensive hemophagocytosis (Fig. 1c). Because of the clinical presentation and positive diagnostic criteria for HLH according to the HLH-2004 protocol [4] (5 out of 8 criteria, including rising ferritin of 7370 μg/L), we suspected malignancy-associated HLH (mal-HLH). We initiated corticosteroids promptly (dexamethasone 10 mg/m) on day 54 after chemotherapy initiation but observed progressive pancytopenia and hemodynamic instability over the subsequent days. According to current recommendations [5] for mal-HLH, we continued to treat the underlying malignancy with the third course of R-CHOEP. Despite these measures, the patient deteriorated and died shortly afterwards in a distributive shock. Further work-up of the histopathological examination of the second bone marrow sample revealed t(14;18) positive HS infiltration and prominent hemophagocytosis within malignant histiocytes (FISH, IHC). The clinical presentation that mimicked secondary HLH was based on refractory HS with bone marrow infiltration and neoplastic hemophagocytosis in the proper sense. Clinically relevant cytopenia due to hemophagocytosis in HS has been rarely described [6–8]. The combination of hemophagocytosis with pancytopenia and inflammatory response syndrome has not been linked to fulminant HS bone marrow infiltration. This finding is relevant for clinical * Felicitas Thol Thol.Felicitas@mh-hannover.de


Dear Editor,
Histiocytic sarcoma (HS) is a rare and aggressive non-Langerhans cell histiocytosis with a poor prognosis [1]. In a subset of cases, HS is clonally related to concurrent hematological malignancies, especially lymphomas [2]. Acquired hemophagocytic lymphohistiocytosis (HLH) is a systemic reactive process that includes macrophage activation with hemophagocytosis in the bone marrow [3].
A 57-year-old woman presented with a progressive hypopharyngeal tumor. B symptoms were absent, and laboratory results were unremarkable. Histologic examination showed a blastic infiltration with monocytoid/histiocytic morphology with CD68, CD163, CD14, and lysozyme expression (CD1a, CD3, CD20, CD34, CD56, CD117, MPO and S100 negative, immunohistochemistry (IHC)) ( Fig. 1a). Staging revealed mediastinal, mesenterial, and retroperitoneal lymphadenopathy as well as an incidental follicular lymphoma (FL) grade 1 in the bone marrow with otherwise unaffected hematopoiesis. Histiocyte infiltration of the bone marrow was excluded. Fluorescence in situ hybridization (FISH) revealed the presence of translocation t(14;18) within the cervical HS as w e l l a s t h e F L o f t h e b o n e m a r r o w ( F i g . 1 b ) . Immunoglobulin heavy chain (IgH) rearrangement was present in the FL but absent in the cervical HS (PCR amplification). We diagnosed HS probably arising from follicular lymphoma.
We initiated a therapy with R-CHOEP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone with etoposide) and documented a stable disease after two cycles of therapy.
Subsequently, therapy continuation was delayed due to persisting fever. Extensive diagnostics and empiric antimicrobial therapies failed. The patient's general condition markedly worsened with onset of a sepsis-like syndrome with a high fever, tachycardia, and hypotension as well as an unexplained progressive pancytopenia. Another bone marrow aspirate showed slightly increased cellularity, normal hematopoiesis, and extensive hemophagocytosis (Fig. 1c).
Because of the clinical presentation and positive diagnostic criteria for HLH according to the HLH-2004 protocol [4] (5 out of 8 criteria, including rising ferritin of 7370 μg/L), we suspected malignancy-associated HLH (mal-HLH). We initiated corticosteroids promptly (dexamethasone 10 mg/m 2 ) on day 54 after chemotherapy initiation but observed progressive pancytopenia and hemodynamic instability over the subsequent days. According to current recommendations [5] for mal-HLH, we continued to treat the underlying malignancy with the third course of R-CHOEP. Despite these measures, the patient deteriorated and died shortly afterwards in a distributive shock.
Further work-up of the histopathological examination of the second bone marrow sample revealed t(14;18) positive HS infiltration and prominent hemophagocytosis within malignant histiocytes (FISH, IHC). The clinical presentation that mimicked secondary HLH was based on refractory HS with bone marrow infiltration and neoplastic hemophagocytosis in the proper sense.
Clinically relevant cytopenia due to hemophagocytosis in HS has been rarely described [6][7][8]. The combination of hemophagocytosis with pancytopenia and inflammatory response syndrome has not been linked to fulminant HS bone marrow infiltration. This finding is relevant for clinical (ZytoLight SPEC BCL2, Zytovision, Bremerhaven, Germany). Orange/ green fusion signal indicated non-rearranged BCL2 gene. Orange and green separate signals confirmed rearranged BCL2 gene (original magnification × 1000). c Day 54 bone marrow aspirate showed prominent wide and polygonal histiocytes with large nuclei and 1-3 prominent nucleoli. The cytoplasm was slightly basophilic and foamy with prominent hemophagocytosis. Pappenheim stain (original magnification × 1000) management of HS. HS may be considered differential diagnosis for inflammatory syndromes with hemophagocytosis such as HLH, especially when refractory to standard therapy.
Authors' contributions Christoph Schünemann, Arnold Ganser, and Felicitas Thol took care of the patient; Gudrun Göhring, Yvonne Lisa Behrens, and Hans-Heinrich Kreipe analyzed the results; Christoph Schünemann and Felicitas Thol formulated, designed, and wrote the paper. All authors read and approved the final manuscript.
Funding Information Open Access funding provided by Projekt DEAL.
Data availability Not applicable.

Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Ethics approval This case study was performed in line with the principles of the Declaration of Helsinki. This article does not contain any studies with human participants performed by any of the authors.
Consent to participate Not applicable.

Consent for publication Not applicable.
Code availability Not applicable.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.